RIMAL B BERA: Open Payments
NPI 1578643656 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$20,526 in 92 payments from 11 companies in 2025. Trend: 2023 $24,642 · 2024 $20,764 · 2025 $20,526
Consulting: $16,289Food & beverage: $2,338Travel & lodging: $1,899
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 21 | $10,487 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $8,466 |
| Alkermes, Inc. | 7 | $409 |
| Neurocrine BioSciences, Inc. | 3 | $304 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $235 |
| ABBVIE INC. | 7 | $198 |
| Vanda Pharmaceuticals Inc. | 13 | $165 |
| Janssen Pharmaceuticals, Inc | 13 | $145 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $75 |
| Luye Pharma (USA) Ltd. | 2 | $29 |
Products named: COBENFY, INGREZZA, CAPLYTA, LYBALVI, ARISTADA, FANAPT, INVEGA SUSTENNA, REJOYN.
Industry payments across CA — which companies pay providers there.
